Wellness Promotion Science Center, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, 5-11-80 Kodatsuno, Kanazawa, 920-0942, Japan.
School of Health Sciences, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
Pharm Res. 2018 Nov 29;36(1):18. doi: 10.1007/s11095-018-2548-5.
Little is known about the affinity and stability of Tc-labeled 2-methoxyisobutylisonitrile (Tc-MIBI) and tetrofosmin (Tc-TF) for imaging of multiple drug resistance transporters in cancer. We examined the affinity of Tc-labeled compounds for these transporters and their stability.
Tc-MIBI and Tc-TF were incubated in vesicles expressing P-glycoprotein (MDR1), multidrug resistance-associated protein (MRP)1-4, or breast cancer resistance protein with and without verapamil (MDR1 inhibitor) or MK-571 (MRP inhibitor). Time activity curves of Tc-labeled compounds were established using SK-N-SH neuroblastoma, SK-MEL-28 melanoma, and PC-3 prostate adenocarcinoma cell lines, and transporter expression of multiple drug resistance was measured in these cells. The stability was evaluated.
In vesicles, Tc-labeled compounds had affinity for MDR1 and MRP1. Tc-TF had additional affinity for MRP2 and MRP3. In SK-N-SH cells expressing MDR1 and MRP1, MK-571 produced the highest uptake of both Tc-labeled compounds. Tc-MIBI uptake with inhibitors was higher than Tc-TF uptake with inhibitors. Tc-TF was taken up more in SK-MEL-28 cells expressing MRP1 and MRP2 than PC-3 cells expressing MRP1 and MRP3. Tc-MIBI was metabolized, whereas Tc-TF had high stability.
Tc-MIBI is exported via MDR1 and MRP1 (MRP1 > MDR1) at greater levels and more quickly compared to Tc-TF, which is exported via MDR1 and MRP1-3 (MRP1 > MDR1; MRP1, 2 > MRP3). Because Tc-MIBI is metabolized, clinical imaging for monitoring MDR and shorter examination times may be possible with an earlier scanning time on late phase imaging. Tc-TF has high stability and accurately reflects the function of MDR1 and MRP1-3.
关于 Tc 标记的 2-甲氧基异丁基异腈(Tc-MIBI)和四氟甲基磷(Tc-TF)用于成像癌症多药耐药转运蛋白的亲和力和稳定性知之甚少。我们检查了 Tc 标记化合物对这些转运蛋白的亲和力及其稳定性。
在表达 P 糖蛋白(MDR1)、多药耐药相关蛋白(MRP)1-4 或乳腺癌耐药蛋白的囊泡中孵育 Tc-MIBI 和 Tc-TF,并在有和没有维拉帕米(MDR1 抑制剂)或 MK-571(MRP 抑制剂)的情况下。使用 SK-N-SH 神经母细胞瘤、SK-MEL-28 黑色素瘤和 PC-3 前列腺腺癌细胞系建立 Tc 标记化合物的时间活性曲线,并测量这些细胞中多药耐药的转运蛋白表达。评估稳定性。
在囊泡中,Tc 标记化合物对 MDR1 和 MRP1 具有亲和力。Tc-TF 对 MRP2 和 MRP3 具有额外的亲和力。在表达 MDR1 和 MRP1 的 SK-N-SH 细胞中,MK-571 对两种 Tc 标记化合物的摄取量最高。与抑制剂一起摄取的 Tc-MIBI 比与抑制剂一起摄取的 Tc-TF 多。在表达 MRP1 和 MRP2 的 SK-MEL-28 细胞中摄取的 Tc-TF 多于表达 MRP1 和 MRP3 的 PC-3 细胞。Tc-MIBI 代谢,而 Tc-TF 稳定性高。
与 Tc-TF 相比,Tc-MIBI 通过 MDR1 和 MRP1(MRP1>MDR1)以更高的水平和更快的速度被排出,Tc-TF 通过 MDR1 和 MRP1-3(MRP1>MDR1;MRP1、2>MRP3)被排出。由于 Tc-MIBI 被代谢,因此通过早期扫描时间进行晚期成像,可能可以进行临床成像以监测多药耐药并缩短检查时间。Tc-TF 稳定性高,能准确反映 MDR1 和 MRP1-3 的功能。